Pharmaceutical sciences research paper says vitamin D Inhibits cancer development
Doctoral research student Shuang Zhou, and Erxi Wu, assistant professor of pharmaceutical sciences, have co-written a paper, “1, 25(OH)2D3 Inhibits Hepatocellular Carcinoma Development Through Reducing Secretion of Inflammatory Cytokines from Immunocytes” which was published in Current Medicinal Chemistry.
Low vitamin D levels in blood are associated with various types of diseases such as osteomalacia and cancer. According to the authors, epidemiological and clinical studies have indicated that low vitamin D activity is not only associated with an increased cancer risk and a more aggressive tumor growth, but also connected with an aggravated liver damage caused by chronic inflammation. Meanwhile, increasing evidence has demonstrated 1,25-(OH)2D3, the most biologically active metabolite of vitamin D, can inhibit inflammatory response in some chronic inflammatory associated cancer. However, the interaction between 1,25-(OH)2D3 and inflammation during hepatocellular carcinoma initiation and progression is not yet clear.
Researchers led by Wu and Qingyong Ma at Xi’an Jiaotong University, China, report an anti-tumorigenesis effect of 1,25-(OH)2D3 via decreasing secretion of inflammatory cytokines in hepatocellular carcinoma.
Wu said, “The effects of vitamin D supplementation on health are uncertain previously, now more and more data show that vitamin D plays very important roles in human health, especially for people living in areas with low sunshine, such as North Dakota. In fact, the toxicity for excess of vitamin D is rare.”
Wu’s research interests include cancer therapeutic targets, drug target proteins, drug discovery and biomarkers. For more information about Wu’s laboratory, visit www.ndsu.edu/pharmsci/faculty_staff/erxi_wu/.
NDSU is recognized as one of the nation's top 108 public and private universities by the Carnegie Commission on Higher Education.